SEOUL, South Korea--(BUSINESS WIRE)--Asan Medical Center and Chemizon, the drug discovery division of Optomagic, Co. Ltd. (KOSDAQ: OPTOMAGIC [A010170]), announced today that they have entered into a multi-year research collaboration to discover and develop novel, small molecule oncology therapeutics.
